- Home
- ACET vs IMA Comparison
ACET vs IMA Comparison
Compare ACET & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACET | IMA |
|---|---|---|
| Founded | 1947 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 65.3M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACET | IMA |
|---|---|---|
| Price | $7.00 | $5.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $56.00 | $16.00 |
| AVG Volume (30 Days) | ★ 111.8K | 30.4K |
| Earning Date | 03-12-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $5.70 |
| 52 Week High | $9.05 | $17.50 |
Technical Indicators
Market Signals| Indicator | ACET | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 37.90 |
| Support Level | $6.54 | N/A |
| Resistance Level | $8.34 | $7.17 |
| Average True Range (ATR) | 0.44 | 0.37 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 17.94 | 7.32 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.